Upadacitinib in Crohn's disease
- Published on 04/02/2024
- Reading time: 4 min.
Axel Dignass a,* , Philip Esters a & Cathrin Flauaus b
a Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany
b AbbVie Deutschland GmbH & Co. KG, Medical Immunology, Wiesbaden, Germany
CONTACT Axel Dignass mailto:Axel.Dignass@agaplesion.de Department of Medicine, Agaplesion Markus Hospital, Goethe University, Wilhelm-Epstein Str. 4, Frankfurt am Main 60431, Germany
Abstract
Introduction The small molecule and oral selective and reversible Janus kinase (JAK) inhibitor upadacitinib has been approved for the treatment of moderate to severe active Crohn's disease (CD) in adult patients since April 2023 by EMA/FDA.
Areas covered The approval is based on the two induction studies a maintenance study showing that upadacitinib induction and maintenance therapy was superior to placebo. The approval of upadacitinib in CD expands the...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Hepato Gastroenterology
Receive our newsletter to stay up to date with the latest news in Hepato Gastroenterology
